Literature DB >> 17075776

Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes.

A Picardi1, N Visalli, A Lauria, C Suraci, R Buzzetti, M K Merola, S Manfrini, C Guglielmi, U V Gentilucci, D Pitocco, A Crinò, C Bizzarri, M Cappa, P Pozzilli.   

Abstract

BACKGROUND: In recent onset of type 1 diabetes, the residual beta cell function, assessed by baseline and/or stimulated C-peptide secretion, can be a useful parameter to establish the extension of beta cell destruction. How metabolic parameters at diagnosis influence residual C-peptide secretion is not well established. PATIENTS AND METHODS: We analyzed 553 consecutive patients with recent onset (<4 weeks) of type 1 diabetes (250 females and 303 males, mean age 15+/-8 years). Baseline and stimulated C-peptide by i.v. glucagon were evaluated using a highly sensitive radio-immunoassay. Metabolic parameters including blood glucose, HbA1c, insulin dose, and BMI were also evaluated.
RESULTS: Baseline and stimulated C-peptide were 0.26+/-0.22 and 0.47+/-0.38 nmol/l and correlated positively with age (p<0.001). There was no significant correlation between C-peptide and blood glucose at diagnosis. BMI was positively correlated with both baseline and stimulated C-peptide secretion (p<0.001). By contrast, HbA1c levels inversely correlated with both baseline and stimulated C-peptide secretion (p<0.001).
CONCLUSION: In type 1 diabetes at diagnosis, baseline and stimulated C-peptide are higher in pubertal and young adult patients compared with pre-pubertal patients suggesting that such parameter can be used as an end point marker for studies aimed at protecting and/or restoring beta cells in patients with substantial beta cell function. High levels of HbA1c and lower BMI are dependent variables of C-peptide values.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17075776     DOI: 10.1055/s-2006-954586

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  9 in total

Review 1.  Type 1 diabetes: A predictable disease.

Authors:  Kimber M Simmons; Aaron W Michels
Journal:  World J Diabetes       Date:  2015-04-15

Review 2.  Combination immunotherapies for type 1 diabetes mellitus.

Authors:  Paolo Pozzilli; Ernesto Maddaloni; Raffaella Buzzetti
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

3.  Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study.

Authors:  D Dabelea; E J Mayer-Davis; J S Andrews; L M Dolan; C Pihoker; R F Hamman; C Greenbaum; S Marcovina; W Fujimoto; B Linder; G Imperatore; R D'Agostino
Journal:  Diabetologia       Date:  2012-09-20       Impact factor: 10.122

4.  German new onset diabetes in the young incident cohort study: DiMelli study design and first-year results.

Authors:  Leonore Thümer; Kerstin Adler; Ezio Bonifacio; Frank Hofmann; Manfred Keller; Christine Milz; Axel Munte; Anette-Gabriele Ziegler
Journal:  Rev Diabet Stud       Date:  2010-11-10

5.  New approach to beta cell function screening by nitric oxide assessment of obese individuals at the population level.

Authors:  Elinton Adami Chaim; Renata Cristina Gobato
Journal:  Int J Gen Med       Date:  2012-05-21

6.  Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden.

Authors:  Maria Thunander; Carina Törn; Christer Petersson; Birger Ossiansson; Jan Fornander; Mona Landin-Olsson
Journal:  Eur J Endocrinol       Date:  2012-03-21       Impact factor: 6.664

7.  Residual β-Cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents.

Authors:  Jesper S Sørensen; Jesper Johannesen; Flemming Pociot; Kurt Kristensen; Jane Thomsen; N Thomas Hertel; Per Kjaersgaard; Caroline Brorsson; Niels H Birkebaek
Journal:  Diabetes Care       Date:  2013-08-29       Impact factor: 19.112

8.  Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients.

Authors:  Francesco Panero; Giulia Novelli; Chiara Zucco; Paolo Fornengo; Massimo Perotto; Olivia Segre; Giorgio Grassi; Paolo Cavallo-Perin; Graziella Bruno
Journal:  Diabetes Care       Date:  2008-11-18       Impact factor: 17.152

9.  Clinical and demographic features among patients with type 1 diabetes mellitus in Henan, China.

Authors:  Liguo Yang; Guangxing Yang; Xialian Li
Journal:  BMC Endocr Disord       Date:  2021-06-28       Impact factor: 2.763

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.